ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck ups Spanish drug capacity 50%

by Alex Scott
October 24, 2016 | APPEARED IN VOLUME 94, ISSUE 42

Merck KGaA has increased its biotech drug production capacity in Spain by 50% by expanding its facility in Tres Cantos, near Madrid, at a cost of $16 million. As part of the project, the German firm has increased staffing at the site by 20% to 170. Tres Cantos is Merck’s primary location for producing the active substances for the fertility treatment Gonal-f and growth hormone disorder treatment Saizen. Merck says it has invested about $275 million in health care manufacturing during 2016.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment